Pharmafile Logo
Pharmafocus logo
Advanced Search

axitinib

Showing 8 posts of 8 posts found.

Pfizer gets early approval for breast cancer drug

February 4, 2015
Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib

The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …

News
Inlyta image

NICE backs Pfizer’s drug for advanced kidney cancer

December 16, 2014
Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo

UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …

News
Inlyta image

NICE U-turn on Pfizer drug Inlyta

March 5, 2014
Research and Development, Sales and Marketing Kidney cancer, NHS, NICE, Pfizer, axitinib, inlyta

NICE has recommended that Pfizer’s kidney cancer drug Inlyta should be used for some patients in England, following a similar …

News
fda_sign_web

Double approval for Pfizer cancer drugs

September 6, 2012
Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc

 Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …

News

Pfizer’s cancer drug meets end points in head-to-head study

May 20, 2011
Research and Development, Sales and Marketing Pfizer, axitinib, rcc

Pfizer’s investigational cancer drug axitinib significantly increased survival in kidney cancer patients when compared to Bayer’s standard treatment Nexavar. New …

News

Key drug launches for 2011

January 20, 2011
Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir

This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …

Feature
Pfizer's Lipitor tablet

Pfizer lung cancer drug gets ‘rolling’ fast-track status in US

January 13, 2011
Sales and Marketing Cancer, NSCLC, axitinib, bosutinib, crizotinib, non-small cell lung cancer

Pfizer has initiated a ‘rolling’ submission for its new oral ALK lung cancer drug crizotinib that could see it on …

News

Pfizer’s axitinib impresses in head-to-head trial with Nexavar

November 22, 2010
Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma

Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025